Stocktoria
Divi's Laboratories Limited DIVISLAB.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Divi's Laboratories Limited financials (annual, from 10-K)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹105.6B | ₹93.6B | ₹78.0B | ₹76.7B |
| Gross profit | ₹64.7B | ₹56.4B | ₹45.3B | ₹44.9B |
| R&D expense | — | ₹270.0M | ₹350.0M | ₹300.0M |
| SG&A expense | — | ₹2.8B | ₹2.1B | ₹2.4B |
| Operating income | ₹29.8B | ₹25.7B | ₹18.3B | ₹20.3B |
| Interest expense | ₹230.0M | ₹20.0M | ₹30.0M | ₹0 |
| Income tax | ₹8.2B | ₹7.2B | ₹5.6B | ₹5.5B |
| Net income | ₹25.7B | ₹21.9B | ₹16.0B | ₹18.2B |
| EPS (diluted) | ₹96.75 | ₹82.53 | ₹60.27 | ₹68.69 |
| Operating cash flow | ₹27.4B | ₹16.5B | ₹12.6B | ₹24.6B |
| Free cash flow | ₹2.2B | ₹2.1B | ₹2.6B | ₹19.9B |
| Cash & equivalents | ₹1.3B | ₹4.2B | ₹3.6B | ₹1.7B |
| Inventory | ₹39.5B | ₹32.4B | ₹31.8B | ₹30.0B |
| Total assets | ₹200.3B | ₹169.3B | ₹154.7B | ₹144.4B |
| Total liabilities | ₹32.7B | ₹19.6B | ₹19.0B | ₹16.7B |
| Shareholders' equity | ₹167.6B | ₹149.7B | ₹135.7B | ₹127.7B |
Growth · year-over-year · Revenue CAGR 11.3%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +12.8% | +20.1% | +1.7% | — |
| Net income growth | +17.2% | +36.9% | -12.3% | — |
| EPS growth | +17.2% | +36.9% | -12.3% | — |
| Free cash flow growth | +1.4% | -16.7% | -87.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · IN · as of 2026-03-31. Figures in INR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.